UCB: positive phase 3 results in lupus

(CercleFinance.com) - UCB and Biogen announce that they have presented positive detailed results from the phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol (DZP) in moderate-to-severe systemic lupus erythematosus at the American College of Rheumatology meeting in Washington.


This new drug candidate met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity.

'A greater response was observed across multiple clinical endpoints in DZP-treated participants, including 50% fewer severe disease flares compared to participants on standard therapy alone', they add.

Copyright (c) 2024 CercleFinance.com. All rights reserved.